Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Raytheon Company (<strong>RTN</strong>) has begun work on enhancements to the combat-proven Patriot Air and Missile Defense System that will make the system more capable, and improve Patriot's already high readiness. The U.S. Army Contracting Command issued the contract, which was funded by the 13 nations that rely on Patriot for their defense. It was announced by the Department of Defense on Feb 1, and will sustain more than 500 highly skilled jobs across four U.S. states.</li><li>Xplore Technologies (<strong>XPLR</strong>) fulfilled an initial $1.3 million order for its XSLATE D10 tablet PCs and is in the process of deploying them as part of the first rugged tablet-based vehicle safety and emissions system ever built for a public or private-sector emissions safety program. The completely mobile system, which is also the first to leverage an Android device, exclusively relies on Xplore XSLATE D10 fully rugged tablet PCs to power the field and back-office workflows of vehicle safety and emissions programs across the United States.</li><li>OncoMed Pharmaceuticals (<strong>OMED</strong>) announced it has enrolled and dosed the first patient in a Phase 1b clinical trial of its anti-DLL4/VEGF bispecific antibody (OMP-305B83) in combination with paclitaxel in patients with platinum-resistant ovarian cancer. OncoMed's anti-DLL4/VEGF bispecific antibody is designed to have anti-angiogenic, anti-cancer stem cell and immuno-modulatory activity.</li><li>Zogenix, Inc. (<strong>ZGNX</strong>) announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome. Study 1504 is a multi-center, two-cohort study to initially assess the pharmacokinetic and safety profile of single doses of ZX008 (fenfluramine hydrochloride), clobazam and valproate when added to stiripentol, followed by a randomized, double-blind, placebo-controlled parallel group evaluation of the efficacy, safety and tolerability of ZX008 as adjunctive antiepileptic therapy to a drug regimen that includes stiripentol, clobazam and valproate. Stiripentol in combination with clobazam and valproate is approved for the treatment of seizures in Dravet syndrome in Europe, Canada, Australia, and Japan.</li><li>Piper Jameson will join Universal Technical Institute (<strong>UTI</strong>), as executive vice president and chief marketing officer effective February 14. She replaces Jeff May, who is leaving the company by mutual agreement.</li><li>i-team Global and Tennant Company (<strong>TNC</strong>) of Minneapolis, Minnesota, U.S.A. (through its Dutch subsidiary Tennant Netherland Holding B.V.), recently formed i-team North America B.V., a joint venture that will operate as the distributor of the i-mop, a heavy-duty scrubber that combines the cleaning performance of an autoscrubber with the agility of a flat mop, in North America. i-team North America will begin selling and servicing the i-mop starting April 3, 2017.</li><li>DelMar Pharmaceuticals (<strong>DMPI</strong>) announced that patient dosing has commenced in a Phase 2 clinical study of its investigational drug VAL-083 (dianhydrogalactitol) for MGMT-unmethylated Avastin (bevacizumab)-naïve recurrent glioblastoma. </li></ul></td> </tr></table>"